DOCSLIB.ORG

Effects of Antibiotics on the Bactericidal Activity of Human Serum

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effects of Antibiotics on the Bactericidal Activity of Human Serum Journal of Antimicrobial Chemotherapy (1982)9,141-148 Effects of antibiotics on the bactericidal activity of human serum Downloaded from https://academic.oup.com/jac/article/9/2/141/712569 by guest on 28 September 2021 Anna Fietta, Patrizia Mangiarotti and Giuliana Gialdroni Grassi Istituto Forlanini, University ofPavia, Italy The interaction between several antibiotics and either normal human serum or EGTA-chelated Mg-treated serum has been tested. Synergism has been observed with rifampicin, tetracycline and doxycycline, but not with minocycline, amino- glycosides (kanamycin, tobramycin, gentamicin, sisomicin and amikacin), chloramphenicol, fosfomycin and erythromycin. It has been demonstrated that Escherichia coli K12 strains bearing plasmids, conferring resistance to tetra- cycline, were killed in the presence of serum. Evidence has been presented that this synergistic action depends on com- plement and can be abolished by serum treatment with ethyleneglycol-tetraacetic acid. Introduction Interference of antimicrobial agents on several reactions involved in the host defence system has been demonstrated by many authors. It has been suggested that resistance to serum bactericidal activity can be an important factor in determining virulence of some Gram-negative bacteria (Durack & Beeson, 1977; Elgefors & Oiling, 1978; Howard & Glynn, 1971; McCabe et al., 1978; Medearis & Kenny, 1968; Oiling et al, 1973; Roantree & Rantz, 1960; Rowley, 1954), and serum bactericidal activity is an important mechanism of defence against bacterial invasion and spread (Agnella, 1978; McCabe et al, 1978; Roantree & Rantz, 1960; Johnston & Strand, 1977). Many Gram-negative Enterobacteriaceae causing bacteraemia are resistant to the bactericidal action of serum (Rowley & Wardlaw, 1958; Vosti & Randall, 1970). Conversion of serum-resistant Escherichia coli to serum-susceptible has been observed after treatment with diphenylamine (Feingold, 1969). Polymyxin B has been shown to be able to induce surface changes in some Gram-negative bacteria leading to serum susceptibility (Prull & Reynolds, 1972; Traub & Sherris, 1970) and subinhibitory concentrations of tetracycline, streptomycin and rifampicin have been shown to increase bacterial susceptibility to the killing activity by serum (Alexander, Gleen Cobbs & Curtiss, 1980; Dutcher et al, 1978). As a part of a study directed to determine the characteristics and the regulatory factors involved in the bactericidal activity of human serum and the possibilities of influencing this in some way, we have investigated the interaction between human 141 0305-7453/82/020141 +08 $01.00/0 © 1982 The British Society for Antimicrobial Chemotherapy 142 A. Fietta, P. Mangiarotti and G. G. Grassi serum and some antibiotics in the killing of rough strains of E. coli, under experimental conditions studying synergism among them.* Materials and methods Chemicals Penassay broth (Antibiotic Medium no. 3) and agar (Antibiotic Medium no. 1) were obtained from Difco; phosphate-buffered saline (PBS) (from Oxoid) and MgCl2 and ethyleneglycol tetraacetic acid (EGTA) (from C. Erba, Milan, Italy); tetracycline and Downloaded from https://academic.oup.com/jac/article/9/2/141/712569 by guest on 28 September 2021 doxycycline were a gift from Pfizer; chloramphenicol from Zambon Farmaceutici; rifampicin from Lepetit; sisomicin from Menarini; tobramycin from Lilly; erythromycin from Sigurta; fosfomycin from Italfarmaco; gentamicin from Essex; amikacin from Bristol; kanamycin was purchased commercially. Organisms The following strains were utilized: high level streptomycin-resistant (MIC > 1000 mg/1) mutant of E. coli K12 J6-2 pro,his,trp, lac; E. coli K12 J6-2 (R1066) and J6-2 (R27). R105 and R27 are R factors conferring transmissible resistance respectively to CTSSu and T. MICs of antibiotics for E. coli K12 were determined in Penassay broth with an inoculum size of 105 cells/ml. Serum The blood of ten healthy donors was allowed to clot for 1 h at room temperature. The sera were separated by centrifugation, pooled, divided into 02 ml samples and stored in liquid nitrogen. Bactericidal assay E. coli J6-2 was grown overnight in Penassay broth at 37°C with agitation and then diluted 1:40 in the same medium and grown to give 06 absorbance at 560 nm. The doubling time and the exponential nature of the growth were regularly checked spectrophotometrically. The bacteria were harvested by centrifugation, washed twice in PBS and resuspended at the concentration of lOVml in PBS. The bactericidal reactions were carried out in 1 ml volumes and incubated,at 37"C in a shaking water bath. Normal human serum at the final concentration of 1 /400 was used in combination with drug, since at this dilution it did not show any killing activity. Inactivation of serum complement was performed by heating at 56°C for 30 min (H56). In order to test the activity only through the activation of the alter- native pathway of complement EGTA and MgCl2 were added at final concentrations of 9 and 4 mM, respectively. In this case a serum dilution of 1:200 was used. The reaction was stopped after 60 min by putting the tubes on ice. Viable counts were obtained by plating suitable dilutions in PBS on Penassay agar plates. The results were expressed as percentage survival, that is as Ns/No x 100, where Ns and No were respectively the number of surviving cells at 60 min and that of cells at zero time. *A preliminary report on some of these findings has been presented by Fietta A., Mangiarotti P., Sacchi F. and G. Gialdroni Grassi Ilth Mediterranean Congress of Chemotherapy, 1980-Nice, October. Antibiotics and bactericidal activity of human serum 143 100 Downloaded from https://academic.oup.com/jac/article/9/2/141/712569 by guest on 28 September 2021 I/I00 1/2001/300 Serum dilution Figure 1. Efficiency of normal human serum (NHS) and EGTA-chelated-Mg2+ treated serum (CHS) bactericidal activity. *, Normal human serum (NHS); •, EGTA-chelated-Mg2+ treated serum (CHS) Samples were incubated for 60 min at 37'C. However, in order more clearly to present the phenomena observed, the results in Figure 1 were expressed as percentage killing, defined as 100—Ns/No x 100. Results Bactericidal activity of normal and EG TA-chelated-Mg2*-treated human serum Incubation of rough strains with human serum results in rapid killing of the cells, that involves either the classical or the alternative pathway of complement activation. In fact, the bactericidal activity is expressed to a different extent by normal human serum (NHS) and by EGTA-chelated-Mg2+ treated serum (CHS). NHS reaction is more efficient than CHS. If serum is sufficiently diluted (1/400 for NHS; 1 /200 for CHS) there is no observable killing (survival = 96 ± 6%) (Figure 1). Table I. Effect of some antibiotics on bactericidal activity of normal human serum (NHS)* Antibiotic alone* Antibioticf + NHSf (1/400) Antibiotic 05 10 2-5 50 05 10 2-5 50 (mg/1) (mg/1) Kanamycin 103 ±5 100±10 95±8 50 100±12 90±6 86±9 56 Tobramycin 95±8 90±ll 77±9 — 75± 7 70+10 68±5 — Gentamicin 102±6 35±4 — — 98±5 39±3 — — Sisomicin 102±12 85±7 88±9 71 ±7 Amikacin 79±9 63±3 36±9 66±10 49±6 30+10 Chloramphenicol 110±10 110±ll 100±9 91 rt 12 106±5 103 ±2 102 + 6 94 + 6 Fosfomycin 100±3 89±8 81 ±8 3O±5 102 + 8 87±8 76+9 29±8 Erythromycin 99±5 96±4 92±6 92±2 98±6 84±6 83 + 5 80+3 •Results are expressed as % of-survival and they represent the mean values of at least three determi- nation. The standard deviations are also reported. tThe concentrations (mg/1) of antibiotic adopted for this test range from 1/16 to 1/2 of MIC. f NHS, Normal human serum diluted 1 /400 (survival % = 96 ± 6). 144 A. Fietta, P. Mangiarotti and G. G. Grassi 100 Downloaded from https://academic.oup.com/jac/article/9/2/141/712569 by guest on 28 September 2021 mg/l mg/l Figure 2. Effects of tetracycline derivatives and rifampicin on NHS bactericidal activity, (a) Tetracycline alone (*); tetracycline plus NHS (•); (b) doxycycline alone (*);doxycycline plus NHS (•); (c) minocycline alone (*); minocycline plus NHS (•); (d) rifampicin alone (*); rifampicin plus NHS (•). Results represent the means of at least four experiments; vertical lines represent the standard deviations from means. Bactericidal activity of human serum plus antibiotics No significant killing was observed when cells were incubated with antibiotics at concentrations ranging from 1/16 to 1/2 of the MICs. MICs of antibiotics for E. coli K12, were the following: aminoglycosides (4-8 mg/l), rifampicin (5 mg/l), tetra- cyclines (1-1-5 mg/l), chloramphenicol (2*5 mg/l), fosfomycin (8 mg/l), erythro- mycin (32 mg/l). When aminoglycosides (tobramycin, sisomicin, amikacin, gentamicin and kanamycin), chloramphenicol, fosfomycin and erythromycin were added to diluted NHS no significant variation of the bactericidal activity was observed after 60 min of incubation (Table I). The same results were obtained with CHS (data not shown). A marked decrease in percentage survival of the cells was shown with rifampicin as well as with tetracycline and doxycycline+ NHS. Minocycline however, showed a lesser effect (Figure 2). At all tested doses the per cent survival with tetracycline, Antibiotics and bactericidal activity of human serum 145 Table II. Bactericidal activity of serum plus tetracycline against E. coli J6-2 (R1066) and J6-2 (R27) Survival (%)t Reagents* J6-2(R1066) J6-2R27 NHS 97 98 H56 100 100 Tetracycline 87 90 Tetracycline + H56 88 99 Downloaded from https://academic.oup.com/jac/article/9/2/141/712569 by guest on 28 September 2021 Tetracycline + NHS 38 28 *NHS and H56 are diluted 1:400; tetracycline is at 50 mg/1, final concentration. tResults are the means of two experiments. IOO 90 Time (min) Figure 3. Time course of bactericidal effect of NHS plus tetracycline or rifampicin (a) • NHS (1/400); • tetracycline alone (25 mg/1; • tetracycline (25 mg/1) plus NHS (1/400) Vertical lines represent the standard deviation from means, (b) • NHS; D rifampicin (1 mg/1); • rifampicin (1 mg/1) plus NHS.
Load more

Recommended publications
  • ZEMDRI (Plazomicin) Injection, for Intravenous Use (Ml/Min) ZEMDRI B Dosing Interval Initial U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION Recommended initial dosage regimen for patients with renal These highlights do not include all the information needed to use impairment is shown in the table below. (2.3) ZEMDRI safely and effectively. See full prescribing Recommended information for ZEMDRI. Estimated CLcr a Dosage for ZEMDRI (plazomicin) injection, for intravenous use (mL/min) ZEMDRI b Dosing Interval Initial U.S. Approval: 2018 Greater than or equal to 60 15 mg/kg Every 24 hours WARNING: NEPHROTOXICITY, OTOTOXICITY, to less than 90 NEUROMUSCULAR BLOCKADE and FETAL HARM Greater than or equal to 30 10 mg/kg Every 24 hours See full prescribing information for complete boxed warning. to less than 60 Nephrotoxicity has been reported with ZEMDRI. The risk Greater than or equal to 15 10 mg/kg Every 48 hours of nephrotoxicity is greater in patients with impaired renal to less than 30 a CLcr estimated by the Cockcroft-Gault formula. (2.3) function, the elderly, and in those receiving concomitant b nephrotoxic medications. (5.1) Calculate dosage using Total Body Weight (TBW). For patients Ototoxicity, manifested as hearing loss, tinnitus, and/or with TBW greater than IBW by 25% or more, use adjusted body weight. (2.3) vertigo, has been reported with ZEMDRI. Symptoms of aminoglycoside associated ototoxicity may be irreversible See Full Prescribing Information for subsequent dosage and may not become evident until after completion of adjustment based on changes in renal function or Therapeutic therapy. (5.2) Drug Monitoring (TDM). (2.3, 2.4). Aminoglycosides have been associated with neuromuscular See Full Prescribing Information for instructions on preparation blockade.
    [Show full text]
  • Antimicrobial Effectiveness of Icanamycin, Tobramycin
    ANTIMICROBIAL EFFECTIVENESS OF ICANAMYCIN, AMINOSIDIN, BB-K8, SISOMICIN, GENTAMICIN AND TOBRAMYCIN COMBINED WITH CARBENICILLIN OR CEPHALOTHIN AGAINST GRAM-NEGATIVE RODS J. KLASTERSKY,B. NYAMUBEYA AND E. VANDENBORRE Service de Mkdecine et Laboratoire d’lnvestigation Clinique (Section des Maladies Infectieuses), Institut Jules Bordet, Centre des Tumeurs de 1’ Unversitt Libre de Bruxelles, Bruxelles, Belgium MANYsevere infections in hospital patients, especially those with altered host defences against infection, are caused by Gram-negative bacilli. Bacteria isolated from patients with disseminated tumours, leukaemias, haematosar- comas and other debilitating diseases are often resistant to many commonly used antibioitics. No single drug regimen has yet been found effective enough to be used for the initial treatment of infections thought to be due to Gram- negative bacilli under these conditions ; a combination of antibiotics is therefore often given empirically (Schimpff et al., 1971 ; Tattersall, Spiers and Darrell, 1972). Another reason for using combinations of antimicrobial agents in the treatment of severe bacterial infections is to take advantage of possible syner- gistic interaction between them. It has been shown that infections treated with combinations that are synergistic in vitro usually have a better clinical outcome than those treated with combinations that are antagonistic or additive (McCabe and Jackson, 1965; Klastersky, Cappel and Daneau, 1972). The investigation of combinations of drugs in vitro may be important, therefore, both to assess the antibacterial spectrum of various combinations and to investigate the frequency with which these combinations are synergistic. The present study explores these two aspects of carbenicillin and cephalothin in combination with different aminoglycosides. Until recently the most com- monly used parenteral aminoglycoside antibiotics were kanamycin and genta- micin.
    [Show full text]
  • Efficacy of Fusidic Acid and Mupirocin in Treatment of Impetigo: a Randomized Clinio- Pharmacological Study
    International Journal of Medical and Health Research Original Research Article International Journal of Medical and Health Research ISSN: 2454-9142 Received: 26-11-2019; Accepted: 21-12-2019; Published: 28-12-2019 www.medicalsciencejournal.com Volume 5; Issue 12; 2019; Page No. 232-234 Efficacy of fusidic acid and mupirocin in treatment of impetigo: A randomized clinio- pharmacological study Dr. Rudresh Tutor, Department of pharmacology, Katihar Medical College, Katihar, Bihar India Abstract Aim: This study compares the efficacy of fusidic acid and mupirocin in treatment of impetigo. Materials and Methods: This was an open label; prospective clinical study was carried out among 60 impetigo patients. The primary end points were evaluated at the baseline, and after one week of treatment. In both groups the test drug was applied locally thrice daily. Statistical analysis was done using paired and unpaired t test. Results: In group I and II; mean number of lesions declined from 4.64 to 0.44 and 4.35 to 0.16 and mean lesion size declined from 3.28 to 0.18 and 3.44 to 0.11 (p≤0.05) respectively. Conclusion: Mupirocin is marginally more effective than fusidic acid but this difference was not statistically significant. Keywords: fusidic acid, mupirocin, efficacy, impetigo Introduction Materials and Methods Impetigo is the most common skin infection in children; it is Study Design caused mainly by Staphylococcus aureus and sometimes A Prospective open label study was conducted for the period by Streptococcus pyogenes [1, 2], The highly contagious of jan 2014 to Nov 2014 among patients with the confirmed nature of impetigo also allows spread from patients to close diagnosis of Impetigo who had attended Out Patient contacts.
    [Show full text]
  • Adjunctive Use of Rifampin for the Treatment of Staphylococcus Aureus Infections: a Systematic Review of the Literature
    REVIEW ARTICLE Adjunctive Use of Rifampin for the Treatment of Staphylococcus aureus Infections A Systematic Review of the Literature Joshua Perlroth, MD; Melissa Kuo, MD; Jennifer Tan, MHS; Arnold S. Bayer, MD; Loren G. Miller, MD, MPH Background: Staphylococcus aureus causes severe life- efit of adjunctive rifampin use, particularly in osteomy- threatening infections and has become increasingly com- elitis and infected foreign body infection models; however, mon, particularly methicillin-resistant strains. Rif- many studies failed to show a benefit of adjunctive therapy. ampin is often used as adjunctive therapy to treat S aureus Few human studies have addressed the role of adjunc- infections, but there have been no systematic investiga- tive rifampin therapy. Adjunctive therapy seems most tions examining the usefulness of such an approach. promising for the treatment of osteomyelitis and pros- thetic device–related infections, although studies were Methods: A systematic review of the literature to iden- typically underpowered and benefits were not always seen. tify in vitro, animal, and human investigations that com- pared single antibiotics alone and in combination with Conclusions: In vitro results of interactions between rif- rifampin therapy against S aureus. ampin and other antibiotics are method dependent and often do not correlate with in vivo findings. Adjunctive Results: The methods of in vitro studies varied substan- rifampin use seems promising in the treatment of clini- tially among investigations. The effect of rifampin therapy cal hardware infections or osteomyelitis, but more de- was often inconsistent, it did not necessarily correlate with finitive data are lacking. Given the increasing incidence in vivo investigations, and findings seemed heavily de- of S aureus infections, further adequately powered in- pendent on the method used.
    [Show full text]
  • Summary Report on Antimicrobials Dispensed in Public Hospitals
    Summary Report on Antimicrobials Dispensed in Public Hospitals Year 2014 - 2016 Infection Control Branch Centre for Health Protection Department of Health October 2019 (Version as at 08 October 2019) Summary Report on Antimicrobial Dispensed CONTENTS in Public Hospitals (2014 - 2016) Contents Executive Summary i 1 Introduction 1 2 Background 1 2.1 Healthcare system of Hong Kong ......................... 2 3 Data Sources and Methodology 2 3.1 Data sources .................................... 2 3.2 Methodology ................................... 3 3.3 Antimicrobial names ............................... 4 4 Results 5 4.1 Overall annual dispensed quantities and percentage changes in all HA services . 5 4.1.1 Five most dispensed antimicrobial groups in all HA services . 5 4.1.2 Ten most dispensed antimicrobials in all HA services . 6 4.2 Overall annual dispensed quantities and percentage changes in HA non-inpatient service ....................................... 8 4.2.1 Five most dispensed antimicrobial groups in HA non-inpatient service . 10 4.2.2 Ten most dispensed antimicrobials in HA non-inpatient service . 10 4.2.3 Antimicrobial dispensed in HA non-inpatient service, stratified by service type ................................ 11 4.3 Overall annual dispensed quantities and percentage changes in HA inpatient service ....................................... 12 4.3.1 Five most dispensed antimicrobial groups in HA inpatient service . 13 4.3.2 Ten most dispensed antimicrobials in HA inpatient service . 14 4.3.3 Ten most dispensed antimicrobials in HA inpatient service, stratified by specialty ................................. 15 4.4 Overall annual dispensed quantities and percentage change of locally-important broad-spectrum antimicrobials in all HA services . 16 4.4.1 Locally-important broad-spectrum antimicrobial dispensed in HA inpatient service, stratified by specialty .
    [Show full text]
  • Treatment Options for Colistin Resistant Klebsiella Pneumoniae: Present and Future
    Journal of Clinical Medicine Review Treatment Options for Colistin Resistant Klebsiella pneumoniae: Present and Future Nicola Petrosillo *, Fabrizio Taglietti and Guido Granata Systemic and Immunocompromised Host Infection Unit, National Institute for Infectious Diseases “L. Spallanzani”, IRCCS–Via Portuense, 292 00149 Rome, Italy * Correspondence: [email protected]; Tel.: +39-065-517-0432 Received: 25 April 2019; Accepted: 25 June 2019; Published: 28 June 2019 Abstract: Multidrug-resistant (MDR) Klebsiella pneumoniae represents an increasing threat to human health, causing difficult-to-treat infections with a high mortality rate. Since colistin is one of the few treatment options for carbapenem-resistant K. pneumoniae infections, colistin resistance represents a challenge due to the limited range of potentially available effective antimicrobials, including tigecycline, gentamicin, fosfomycin and ceftazidime/avibactam. Moreover, the choice of these antimicrobials depends on their pharmacokinetics/pharmacodynamics properties, the site of infection and the susceptibility profile of the isolated strain, and is sometimes hampered by side effects. This review describes the features of colistin resistance in K. pneumoniae and the characteristics of the currently available antimicrobials for colistin-resistant MDR K. pneumoniae, as well as the characteristics of novel antimicrobial options, such as the soon-to-be commercially available plazomicin and cefiderocol. Finally, we consider the future use of innovative therapeutic strategies in development, including bacteriophages therapy and monoclonal antibodies. Keywords: Klebsiella pneumoniae; colistin-resistant; cefiderocol; ceftazidime/avibactam; colistin; fosfomycin; plazomicin; tigecyclin 1. Introduction The global rise of multidrug-resistant (MDR) gram-negative bacteria represents an increasing threat to human health [1–3]. Among gram-negative bacteria, the rod-shaped bacterium K.
    [Show full text]
  • What's Hot in Infectious Diseases
    What’s Hot in Infectious Diseases - Clinical Science? Stan Deresinski MD FACP FIDSA Clinical Professor of Medicine Stanford University No Disclosures 1884 Pakistan: Salmonella enterica serovar typhi MDR - XDR • November 2016, Hyderabad Pakistan Integrated transposon • Appearance of a H58 haplotype strain encoding amp, chloro, resistant to antibiotics of 5 classes T/S resistance + gyrA • Resulted from acquisition of single mutation chromosomal and plasmid mediated mechanisms by dominant H58 haplotype IncY plasmid* • Plasmid carrying qnrS, blaCTX-M-15 acquired from E. coli blaCTXM-15 • Susceptible only to imipenem, qnrS azithromycin MDR – chloramphenicolR, T/SR, ampicillinR XDR – MDR plus ceftriaxoneR, fluoroquinoloneR mBio. January/February 2018 Volume 9 Issue 1 e00105-18 XDR Typhoid – Pakistan & Beyond • Rapid increase in case numbers with spread to Karachi WHO prequalified use of conjugate vaccine (Typbar-TCV®) – single dose, immunogenic in children >6 months of age • At least 3 travelers returned with infection - one to UK, 2 to US July 11, 2018 “Novartis joins the Big Pharma exodus out of antibiotics, dumping research, cutting 140 and out-licensing programs” https://endpts.com/novartis-joins-the-big-pharma-exodus-out-of-antibiotics-dumping-research-cutting-140-and-out-licensing-programs/ https://gizmodo.com/novartis-becomes-the-latest-pharma-company-to-give-up-o-1827524081 Selected Antibacterials Expected to Be Submitted to the FDA for Approval by Mid-2019 https://cdn2.hubspot.net/hubfs/498900/Jul2018_DrugPriceForecast_Media_FINAL.pdf Cefiderocol • Siderophore cephalosporin • Panel (N=315) of carbapenemase- producing MDR GNR – MIC <4 mcg/ml: • Enterobacteriaeceae – 87.5% • P. aeruginosa - 100% • A. baumanii - 89% • Activity by carbapenemase type: • A – 91.8% B - 74.8% D – 98.0% IDWeek 2017.
    [Show full text]
  • Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies
    Arrhythmogenic potential of drugs FP7-HEALTH-241679 http://www.aritmo-project.org/ Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies V 1.3 Draft Lead beneficiary: EMC Date: 03/01/2010 Nature: Report Dissemination level: D5.2 Report on Common Study Protocol for Observational Database Studies WP5: Conduct of Additional Observational Security: Studies. Author(s): Gianluca Trifiro’ (EMC), Giampiero Version: v1.1– 2/85 Mazzaglia (F-SIMG) Draft TABLE OF CONTENTS DOCUMENT INFOOMATION AND HISTORY ...........................................................................4 DEFINITIONS .................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. ABBREVIATIONS ......................................................................................................................6 1. BACKGROUND .................................................................................................................7 2. STUDY OBJECTIVES................................ ERRORE. IL SEGNALIBRO NON È DEFINITO. 3. METHODS ..........................................................................................................................8 3.1.STUDY DESIGN ....................................................................................................................8 3.2.DATA SOURCES ..................................................................................................................9 3.2.1. IPCI Database .....................................................................................................9
    [Show full text]
  • 3.2.3 Interactions of Emerging Contaminant
    Interactions of Emerging Contaminants- Antibiotics with Functionalized Biochar Prof John L Zhou, Md. B. Ahmed School of Civil and Environmental Engineering UTS 21 August 2018 Graphics created by by created Graphics volupta re conecum Ullupta doluptuam. et pe evelignis BIOCHAR 2018 2 Outline of the Talk 1. Antibiotic residues in the environment 2. Preparation and characterization of functionalized biochar 3. Application of functionalized biochar in antibiotic removal from water and wastewater 4. Conclusions BIOCHAR 2018 3 Emerging Contaminants in the Environment • Pharmaceuticals and personal care products (PPCPs) • Nano-materials • Disinfection by-products • New pesticides • Degradation products Halpern et al. (2008) Science 319, 948 BIOCHAR 2018 4 Pharmaceutical Residues in the Environment • Of the greatest concern worldwide are pharmaceuticals, in particular antibiotic residues: ü Produced in large quantity, e.g. > 25000 tons per annum produced in China alone. ü Between 80-90% are excreted unmetabolized once consumed in human and animals. ü Poorly removed in sewage treatment plants. ü Potential to cause antibiotic resistance, leading to the so-called “superbugs” with antibiotic resistance genes. BIOCHAR 2018 5 Comparative Removal Efficiency of Emerging Contaminants Ahmed et al. (2017) JHM 323, 274-298 BIOCHAR 2018 6 Antibiotic Resistance Germs Take a Bite Out of Antibiotics D-CYCLOSERINE AMIKACIN GENTAMICIN KANAMYCIN SISOMICIN CHLORAMPHENICOL THIAMPHENICOL CARBENICILLIN DICLOXACILLIN PENICILLIN G VANC OM YC IN CIPROFLOXACIN LEVOFLOXACIN NALIDIXIC ACID MAFENIDE Taste test. Harvard University researchers Morten SULFAMETHIZOLE SULFISOXAZOLE Sommer and Gautam Dantas and colleagues used TRIMETHOPRIM soil samples from a Massachusetts forest and a cornfield (inset) to screen for antibiotic-eating Growth No Growth microbes. Science (2008) 320, 33 BIOCHAR 2018 7 Antibiotics in Water and Sediments from Mariculture Sites in China Chen et al.
    [Show full text]
  • Point Prevalence Survey of Healthcare-Associated Infections and Antimicrobial Use in European Acute Care Hospitals
    TECHNICAL DOCUMENT Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals Protocol version 5.3 www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT Point prevalence survey of healthcare- associated infections and antimicrobial use in European acute care hospitals Protocol version 5.3, ECDC PPS 2016–2017 Suggested citation: European Centre for Disease Prevention and Control. Point prevalence survey of healthcare- associated infections and antimicrobial use in European acute care hospitals – protocol version 5.3. Stockholm: ECDC; 2016. Stockholm, October 2016 ISBN 978-92-9193-993-0 doi 10.2900/374985 TQ-04-16-903-EN-N © European Centre for Disease Prevention and Control, 2016 Reproduction is authorised, provided the source is acknowledged. ii TECHNICAL DOCUMENT PPS of HAIs and antimicrobial use in European acute care hospitals – protocol version 5.3 Contents Abbreviations ............................................................................................................................................... vi Background and changes to the protocol .......................................................................................................... 1 Objectives ..................................................................................................................................................... 3 Inclusion/exclusion criteria .............................................................................................................................. 4 Hospitals .................................................................................................................................................
    [Show full text]
  • Author Section
    AUTHOR SECTION patients who may be treated in the outpatient setting with oral M antimicrobials from patients in whom hospitalization and parenteral therapy is appropriate. Over the past decade, dramatic escalation in antimicrobial resistance among common respiratory pathogens poses Macartney K.K. et al. Nosocomial respiratory syncytial virus infections: the obstacles to antibiotic choices.We review the microbiology of com- cost-effectiveness and cost-benefit of infection control. Pediatrics. 2000; munity-acquired pneumonia, and the therapeutic strategies that are 106(3) : 520-6.p Abstract: OBJECTIVE:To determine the cost- clinically and cost effective. effectiveness and cost-benefit of an infection control program to reduce nosocomial respiratory syncytial virus (RSV) transmission in Lyon W.R. et al. A role for trigger factor and an rgg-like regulator in the tran- a large pediatric hospital. DESIGN: RSV nosocomial infection (NI) scription, secretion and processing of the cysteine proteinase of Streptococcus was studied for 8 years, before and after intervention with a target- pyogenes. EMBO J. 1998; 17(21) : 6263-75.p Abstract: The abili- ed infection control program.The cost-effectiveness of the interven- ty of numerous microorganisms to cause disease relies upon the tion was calculated, and cost-benefit was estimated by a case-control highly regulated expression of secreted proteinases. In this study, comparison. SETTING: Children’s Hospital of Philadelphia, a 304- mutagenesis with a novel derivative of Tn4001 was used to identify bed pediatric hospital. PATIENTS: All inpatients with RSV infec- genes required for the expression of the secreted cysteine proteinase tion, both community- and hospital-acquired. INTERVENTION: (SCP) of the pathogenic Gram-positive bacterium Streptococcus Consisted of early recognition of patients with respiratory symp- pyogenes.
    [Show full text]
  • Aminoglycoside Antibiotic-Inactivating Enzymes in Actinomycetes Similar
    Proc. Nat. Acad. Sci. USA Vol. 70, No. 8, pp. 2276-2280, August 1973 Aminoglycoside Antibiotic-Inactivating Enzymes in Actinomycetes Similar to Those Present in Clinical Isolates of Antibiotic-Resistant Bacteria (streptomyces/origin of R-factors/gentamicin-acetate) RAOUL BENVENISTE* AND JULIAN DAVIESt Department of Biochemistry, College of Agricultural and Life Sciences, University of Wisconsin-Madison, Madison, Wis. 53706 Communicated by Henry Lardy, May 11, 1973 ABSTRACT Various species of Streptomyces possess their cellular dimensions, their cytology, and their genetics aminoglycoside-modifying enzymes. Streptomyces kana- place them among the bacteria (5, 6). One of the most striking myceticus contains an enzyme that acetylates the 6'-amino the extent to which they group of kanamycin A and B, gentamicin Cla, and neo- properties of the actinomycetes is mycin. Streptomyces spectabilis produces an enzyme that produce antibiotics; most of the aminoglycoside antibiotics acetylates the 2'-amino group of the hexose ring of genta- (streptomycin, neomycin, kanamycin, gentamicin, tobra- micin Cia. These enzymes catalyze reactions identical to mycin, and lividomycin) are produced by them. those catalyzed by enzymes found in gram-negative bac- Enzymes that modify other antibiotics have been isolated teria containing R(antibiotic resistance)-factors. The dis- covery of these enzymes suggests the possibility of an from Streptomyces species; in studies on the biosynthesis of evolutionary relationship between the aminoglycoside- streptomycin in Streptomyces bikiniensis, Miller and Walker inactivating enzymes (produced by resistance determi- (3, 8) and Nimi and coworkers (9, 10) found three enzymes nants) in bacteria containing R-factors and similar en- that phosphorylated streptomycin. In addition, Argoudelis zymes found in the actinomycetes.
    [Show full text]